Examkin

Question

Difficulty: HardPreventive Care and Screening

Seeking to establish care, a 38-year-old woman arrives at the ambulatory clinic for a comprehensive wellness evaluation. She was diagnosed with systemic lupus erythematosus (SLE) complicated by class III lupus nephritis five years ago. Her disease has been clinically quiescent for the past three years on a maintenance regimen of mycophenolate mofetil and 10 mg of daily prednisone. She feels well and has no new symptoms. Her husband accompanies her, and she notes they have been mutually monogamous for the past decade.

Review of her preventive health records reveals the following:
* Dual-energy x-ray absorptiometry (DEXA) scan performed 6 months ago showed normal bone mineral density.
* Following her SLE diagnosis, she completed three consecutive normal annual cervical cytology exams. Her most recent screening, performed 2 years ago, was a negative cervical cytology with a negative high-risk HPV co-test.
* She received the 20-valent pneumococcal conjugate vaccine (PCV20) 1 year ago.
* She received the inactivated quadrivalent influenza vaccine 3 weeks ago at a community health fair.

Based on current immunization and screening guidelines, which of the following is the most appropriate next step in preventive care for this patient?

  1. Administer the recombinant zoster vaccineAnswer
  2. B
    Administer the live-attenuated varicella vaccine
  3. C
    Perform cervical cytology with high-risk HPV co-testing
  4. D
    Administer the 23-valent pneumococcal polysaccharide vaccine (PPSV23)
  5. E
    Order screening mammography

Answer

Administer the recombinant zoster vaccine
The Advisory Committee on Immunization Practices (ACIP) recommends two doses of the recombinant zoster vaccine (RZV) for adults aged 19 years and older who are or will be immunodeficient or immunosuppressed due to disease or therapy. This patient's ongoing maintenance immunosuppression with mycophenolate mofetil and prednisone places her at high risk for herpes zoster reactivation. Therefore, administering the recombinant zoster vaccine is the most appropriate next step in her preventive care.

Step-by-Step Solution

1
Assess the patient's immune status and comorbidities.
The patient has systemic lupus erythematosus and is actively taking mycophenolate mofetil and prednisone, classifying her as significantly immunocompromised.
Immunocompromised status fundamentally alters the standard age cutoffs and intervals for both vaccinations and cancer screenings.
2
Evaluate vaccine indications based on age and immune status.
While routine zoster vaccination begins at age 50, the recombinant zoster vaccine is specifically indicated for immunocompromised adults aged 19 years and older. She requires this vaccine.
Immunosuppression places her at high risk for herpes zoster reactivation.
3
Rule out contraindicated interventions.
The live-attenuated varicella vaccine is absolutely contraindicated due to her active use of antimetabolite therapy (mycophenolate).
Live vaccines pose a risk of disseminated infection in severely immunocompromised hosts.
4
Evaluate the current status of age- and risk-appropriate cancer screening and other vaccines.
Cervical co-testing is on a 3-year interval for immunosuppressed patients and is not due. PCV20 provides complete pneumococcal coverage without needing PPSV23. Mammography does not begin until age 40.
Ensures no other competing guideline takes priority or is currently due.

Key Concept

Preventive Care Guidelines in Immunocompromised Adults
Rate this question

Topics

Preventive Care and Screening

More questions from this topic